Tag Archives: Blueprint Medicines

November, 2018

15 November
Blueprint Medicines’ Avapritinib Demonstrates Positive Results in Clinical Trial in Patients with Advanced Gastrointestinal Stromal Tumors

CAMBRIDGE, Mass., Nov. 15, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT and PDGFRA inhibitor in development for patients with …
Share

15 June
Blueprint Avapritinib Demonstrates Profound and Durable Clinical Activity in Advanced Systemic Mastocytosis Trial

CAMBRIDGE, Mass., June 15, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data from its ongoing Phase 1 EXPLORER clinical trial of avapritinib, a potent and highly selective KIT and PDGFRA inhibitor in development for patients with …
Share

10 November
Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data for BLU-285, a potent and highly selective KIT and PDGFRα inhibitor in development as a potential …
Share

9 September
Blueprint Medicines’ New Drug Discovery Program to Target PRKACA Kinase Fusions for Liver Cancer Treatment

CAMBRIDGE, Mass., Sept. 9, 2016 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions for the treatment of fibrolamellar carcinoma …
Share

16 March
Blueprint Medicines and Roche Enter Cancer Immunotherapy Deal

CAMBRIDGE, Mass., March 15, 2016 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it has entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, …
Share

3 March
Blueprint Medicines and Alexion Partner for Drugs Targeting a Rare Genetic Disease

Rare disease maker Alexion Pharmaceuticals has partnered with Blueprint Medicines to develop drugs for a rare genetic disease. Blueprint Medicines said that the companies have formed a strategic collaboration to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which causes a rare genetic disease. Blueprint …
Share